Prestige Consumer Healthcare (NYSE:PBH) Issues FY 2027 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.550-4.650 for the period, compared to the consensus EPS estimate of 4.580. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Analyst Ratings Changes

Several equities research analysts recently commented on PBH shares. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Finally, Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $53.13 on Thursday. The firm has a market capitalization of $2.52 billion, a P/E ratio of 13.59, a P/E/G ratio of 1.67 and a beta of 0.34. Prestige Consumer Healthcare has a 52 week low of $42.62 and a 52 week high of $75.31. The stock has a 50 day moving average price of $48.55 and a two-hundred day moving average price of $56.14. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.10. The firm had revenue of $265.71 million for the quarter, compared to the consensus estimate of $250.34 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Equities analysts forecast that Prestige Consumer Healthcare will post 4.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp raised its holdings in shares of Prestige Consumer Healthcare by 1.4% in the 4th quarter. State Street Corp now owns 1,992,497 shares of the company’s stock valued at $122,917,000 after acquiring an additional 27,721 shares in the last quarter. Morgan Stanley increased its position in shares of Prestige Consumer Healthcare by 6.3% in the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock worth $74,209,000 after purchasing an additional 71,078 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Prestige Consumer Healthcare by 5.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock worth $45,568,000 after purchasing an additional 35,126 shares during the last quarter. Bank of America Corp DE raised its stake in Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after purchasing an additional 115,459 shares in the last quarter. Finally, Raymond James Financial Inc. raised its stake in Prestige Consumer Healthcare by 15.7% in the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock valued at $39,807,000 after purchasing an additional 86,373 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).